Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx

5

XI.ba Nonrespiratory AE of interest

5
Last update : 21/04/2019
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Atezolizumab
2
Avelumab
1
CTLA4 blocking immunotherapy
3
Camrelizumab
1
Ipilimumab
4
Lambrolizumab
4
Nivolumab
5
PD-1/PD-L1-inhibitors or blocking agents/drugs
5
Pedelizumab
1
Pembrolizumab
5
Tislelizumab
1
Tremelimumab
1
Vaccination - Immunization
2
Vaccines
3
Zimberelimab
1

Publications

Acute neurological adverse events during immune checkpoint inhibition therapy in patients with melanoma brain metastases.
Melanoma research 2019 Oct;29;516-521 2019 Oct
Misleading impaired liver function in a non-small-cell lung cancer patient treated with pembrolizumab: a case report.
Anti-cancer drugs 2019 Aug;30;e0764 2019 Aug
Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy.
Cardiology in review 2019;27;97-107 2019
Identifying and managing the adverse effects of immune checkpoint blockade.
Journal of thoracic disease 2018 Feb;10;S480-S489 2018 Feb

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies